Positive axillary sentinel lymph node: Is axillary dissection always necessary?

Breast

Volumn 20, Issue SUPPL. 3, 2011, Pages

  Galimberti, Viviana ^a   Chifu, Camelia ^a   Rodriguez Perez, Suanly ^a   Veronesi, Paolo ^a,b   Intra, Mattia ^a   Botteri, Edoardo ^a   Mastropasqua, Mauro ^a   Colleoni, Marco ^a   Luini, Alberto ^a   Veronesi, Umberto ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Axillary dissection; Breast cancer; Micrometastasis; Sentinel node

Indexed keywords

ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MASTECTOMY; MICROMETASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SENTINEL LYMPH NODE;

EID: 80054862943     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/S0960-9776(11)70303-4     Document Type: Article

References (27)

1. Veronesi U, Galimberti V, Paganelli G, et al. Axillary metastases in breast cancer patients with negative sentinel nodes: a follow-up of 3548 cases. Eur J Cancer 2009, 45(8):1381-1388.
2. Veronesi U, Viale G, Paganelli G, et al. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg 2010, 251(4):595-600.
3. Mansel RE, Goyal A European studies on breast lymphatic mapping. Semin Oncol 2004, 31(3):304-310.
4. Dabbs DJ, Fung M, Landsittel D, McManus K, Johnson R Sentinel lymph node micrometastasis as a predictor of axillary tumor burden. Breast J 2004, 10(2):101-105.
5. Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N EnglJ Med 2003, 349:546-553.
6. Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18J. Clin Oncol 1997, 15:2483-2493.
7. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. NEnglJ Med 2002, 347:1233-1241.
8. Gadd M, Harris J, Taghian A, et al. Prospective study of axillary radiation without axillary dissection for breast cancer patients with a positive sentinel node. Presented at San Antonio Breast Cancer Symposium,.
9. Kim T, Giuliano AE, Lyman GH Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: A meta-analysis. Cancer December 8-11, 2005, San Antonio, TX. 2006, 106:4-16.
10. Noguchi M Avoidance of axillary lymph node dissection in selected patients with node-positive breast cancer. EurJ Surg Oncol 2008, 34(2):129-134.
11. Katz A, Smith BL, Golshan M, et al. Nomogram for the prediction of having four or more involved nodes for sentinel lymph node-positive breast cancer. J Clin Oncol 2008, 26:2093-2098.
12. Peintinger F, Reitsamer R, Stranzl H, et al. Comparison of quality of life and arm complaints after axillary lymph node dissection vs sentinel lymph node biopsy in breast cancer patients. BrJ Cancer 2003, 89:648-652.
13. Purushotham AD, Upponi S, Klevesath MB, et al. Morbidity after sentinel lymph node biopsy in primary breast cancer: Results from a randomized controlled trialj. Clin Oncol 2005, 23:4312-4321.
14. Truong PT, Vinh-Hung V, Cserni G, et al. The number of positive nodes and the ratio of positive to excised nodes are significant predictors of survival in women with micrometastatic node-positive breast cancer. Eur J Cancer 2008, 44:1670-1677.
15. Standards of the Commission on Cancer, volume II. Registry Operations and Data Standards 1998, Commission on Cancer, Chicago, IL.
16. Van Zee KJ, Manasseh DM, Bevilacqua JL, et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol 2003, 10:1140-1151.
17. Bilimoria KY, Bentrem DJ, Hansen NM, et al. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin. Oncol 2009, 27:2946-2953.
18. Yi M, Giordano SH, Meric-Bernstam F, et al. Trends in and outcomes from sentinel lymph node biopsy (SLNB) alone vs. SLNB with axillary lymph node dissection for node-positive breast cancer patients: experience from the SEER database. Ann Surg Oncol 2010, 17(Suppl 3):343-351.
19. de Boer M, van Deurzen CH, van Dijck JA, et al. Micrometastases or isolated tumor cells and the outcome of breast cancer. N Engl J Med 2009, 361(7):653-663.
20. Galimberti V, Botteri E, Chifu C, et al. Can we avoid axillary dissection in the micrometastatic sentinel node in breast cancer?. Breast Cancer Res Treat 2011, in press. 10.1007/sl0549-011-1486-2.
21. Straver ME, Meijnen P, van Tienhoven G, et al. Role of axillary clearance after a tumor-positive sentinel node in the administration of adjuvant therapy in early breast cancer. J Clin Oncol 2010, 28(5):731-737.
22. Galimberti V International Breast Cancer Study Group Trial of Sentinel Node Biopsy. J Clin Oncol 2006, 24(1):210-211.
23. Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg 2010, 252(3):426-432.
24. Giuliano AE. ACOSOG Z0011: A randomized trial of axillary node dissection in women with clinical T1-2N0M0 breast cancer who have a positive sentinel node. ASCO Annual Meeting 2010, abstract.
25. Morrow M Patterns of care with a positive sentinel node: echoes of an opportunity missed. Ann Surg Oncol 2009, 16(9):2429-2430.
26. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology Breast, version 2. 2008.
27. van den Hoven I, Kuijt GP, Voogd AC, van Beek MW, Roumen RM Value of Memorial Sloan-Kettering Cancer Center nomogram in clinical decision making for sentinel lymph node-positive breast cancer. BrJSurg 2010, 97(ll):1653-1658.